TEMENOS
16.6.2020 09:09:06 CEST | Business Wire | Press release
Intelligence Sales League Table 2020 (SLT) . Temenos was also named a regional leader in both Europe and Americas. Temenos, with its AI and advanced cloud technology, continues to be the undisputed leader in the main product categories in the IBS League Table with the greatest number of competitors.
Temenos has been ranked as the best-selling core banking system for 15 years, as well as the best-selling vendor for digital banking for the fourth consecutive year. For 21 years running, Temenos has demonstrated consistent leadership, placing in the top two positions for core banking systems. In this year’s Sales League Table, Temenos led in nine categories, including:
- #1 Digital banking and channels with Temenos Infinity, gaining 38 new name deals
- #1 Best-selling core banking system with Temenos Transact, securing 51 new name customer deals
- #1 Retail payments system with 51 new deals for Temenos Payments
- #1 Risk management system, closing 53 new deals with Temenos Financial Crime Mitigation
- #1 Regional Leader in Europe, working with ABN AMRO and challenger banks such as Lunar and Alba
- #1 Regional Leader in Americas, partnering with innovative banks such as CWB Financial Group
- #2 Regional Leader in the Middle-East and Africa with key clients such as Egyptian National Post Organization
- #2 Regional Leader in APAC with innovative clients such as TSB with Temenos Infinity Digital Onboarding and Virgin Money Australia
- #2 Islamic Banking, partnering with the world's largest Islamic bank, Al Rajhi Bank
Max Chuard, Chief Executive Officer, Temenos, said: “It’s a great honor to be recognized as the best-selling banking software provider with the most modern technology across the main product categories of digital, core banking, retail payments, and risk management systems. Now more than ever we see an acceleration in digital and cloud adoption – banks need agile, modern banking technology across the front and back office. We offer our offer our clients, both established banks and new entrants, the winning combination of the richest banking functionality and the most advanced cloud-native, cloud-agnostic technology. We deliver solutions for the ‘New Normal’ that give our clients agility, speed to market, hyper-personalized services at the front end and automation and operational excellence in the back office. The IBS report reconfirms Temenos as global powerhouse and the world’s #1 banking software company and I would like to thank our customers, partners and employees for helping us achieve this exciting milestone.”
IBS’ Sales League Table Panel, said: “2019 was a record-breaking year for our Sales League Table, with nearly 900 validated deals globally and the highest level of vendor participation to-date. Temenos’ success was notable due to achieving #1 positions in the most intensely competitive categories including digital banking, core banking, retail payments and risk management systems. At IBS Intelligence, we are seeing banks re-visiting their digital transformation plans to support their businesses through the current COVID-19 crisis. 2020 will be an interesting year for our industry and we will be continuing to track new deals and trends to support our clients worldwide.”
Temenos continues to relentlessly focus on innovation, investing 20% of its revenue in R&D – more than any other provider in the industry. The IBS Intelligence Sales League Table is the global barometer for sales performance of banking platforms ranging from retail, to private, to Islamic, to digital-only and universal banking. The SLT provides a vital tool to executives in banks for selecting vendors for RFIs and influences vendor selection across conventional and digital banking.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005373/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom